A phase II study of ALX-0171 in Japanese infants hospitalised as a result of a Respiratory syncytial virus (RSV) infections

Trial Profile

A phase II study of ALX-0171 in Japanese infants hospitalised as a result of a Respiratory syncytial virus (RSV) infections

Planning
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs ALX 0171 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2017 New trial record
    • 24 Aug 2017 According to an Ablynx media release, the company plans to file for regulatory approval to enable the start of this trial and expects to commence the trial in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top